RS17
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape[1].
Product Specifications
CAS Number
2415545-08-1
UNSPSC
12352209
Target
CD47; Interleukin Related
Type
Peptides
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rs17.html
Purity
99.82
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
Molecular Formula
C96H130N30O26
Molecular Weight
2120.24
References & Citations
[1]Wang X, et al. An antitumor peptide RS17‐targeted CD47, design, synthesis, and antitumor activity[J]. Cancer Medicine, 2021, 10 (6) : 2125-2136.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
